MDS,
Showing 1 - 25 of 3,289
AML/MDS, Acute Myeloid Leukemia, MDS Trial (Danvatirsen, Danvatirsen + Venetoclax)
Not yet recruiting
- AML/MDS
- +2 more
- Danvatirsen
- Danvatirsen + Venetoclax
- (no location specified)
Aug 14, 2023
MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)
Recruiting
- Myelodysplastic Syndromes
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
Feb 16, 2023
MDS Trial (Roxadustat in combination with retinoic acid)
Not yet recruiting
- Myelodysplastic Syndromes
- Roxadustat in combination with retinoic acid
- (no location specified)
Aug 26, 2023
Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML) Trial in Seoul
Active, not recruiting
- Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
-
Seoul, Korea, Republic ofAsan Medical Center, University of Ulsan College of Medicine
Oct 19, 2023
MDS Trial in Houston (Luspatercept)
Not yet recruiting
- Myelodysplastic Syndromes
-
Houston, TexasM D Anderson Cancer Center
Nov 2, 2023
Cancer, MDS-EB, MDS Trial in Athens, Southampton, Sheffield (INKmune)
Recruiting
- Cancer
- +4 more
- INKmune
-
Athens, Attiki, Greece
- +2 more
Jul 3, 2023
MDS Trial in Beijing (Lenalidomide, Azacitidine)
Not yet recruiting
- Myelodysplastic Syndromes
-
Beijing, ChinaPeking union medical college hospital
Aug 16, 2023
MDS Trial in Beijing (Roxadustat, Luspatercept)
Not yet recruiting
- Myelodysplastic Syndromes
-
Beijing, ChinaPeking union medical college hospital
Aug 17, 2023
Lower-risk Myelodysplastic Syndrome Trial in Tampa (JSP191)
Recruiting
- Lower-risk Myelodysplastic Syndrome
-
Tampa, FloridaMoffitt Cancer Center
Jun 20, 2023
MDS, Myelodysplastic Anemia, Myelodysplastic Syndrome With Isolated Del(5Q) Trial (description of MDS pzatient cohort)
Recruiting
- Myelodysplastic Syndromes
- +5 more
- description of MDS pzatient cohort
-
Brest, FranceChu Brest
Oct 27, 2022
Lower-risk MDS Patients
Recruiting
- MDS
-
Leipzig, GermanyUniversity Hospital Leipzig
Oct 13, 2022
Refractory MDS Patients
Active, not recruiting
- Myelodysplastic Syndromes
-
Stanford, CaliforniaStanford MDS Center
Aug 1, 2022
MDS/MPN Trial in Nanjing (Azacitidine (AZA) with Ruxolitinib)
Recruiting
- MDS/MPN
- Azacitidine (AZA) with Ruxolitinib
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital of Nanjing Medical University
Apr 17, 2023
MDS, Chronic Myelomonocytic Leukemia Trial in Tianjin (BC3402, Azacitidine)
Recruiting
- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital, Chinese Acade
Jul 30, 2023
Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)
Recruiting
- Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
-
Ocala, Florida
- +3 more
Jan 30, 2023
Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), Paroxysmal Nocturnal Hemoglobinuria (PNH) Trial run
Recruiting
- Severe Aplastic Anemia (SAA)
- +2 more
- Cyclophosphamide
- Peripheral Blood Stem Cells
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 28, 2023
AML, MDS Trial in Tianjin (XZB-0004)
Not yet recruiting
- AML
- MDS
-
Tianjin, Tianjin, ChinaHematology Hospital, Chinese Academy of Medical Sciences
Feb 13, 2023
MDS Over Time - Comparison of Treated vs Untreated Patients
Completed
- Myelodysplastic Syndromes
-
Vienna, AustriaHanusch Krankenhaus, 3.Medizinische Abteilung
Nov 21, 2022
Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Neoplasm
- Magrolimab
- +2 more
- (no location specified)
Apr 24, 2023
Immunophenotyping of Blast Cells and Immune Effector Cells in
Completed
- Leukemia
- Blood and Marrow sample
-
Marseille, FranceAssistance Publique - Hopitaux de Marseille
Jan 23, 2023
MDS Trial (Decitabine/Cedazuridine, Magrolimab)
Not yet recruiting
- Myelodysplastic Syndromes
- (no location specified)
Apr 18, 2023
Hematologic Malignancy Trial in Guangzhou (BC3402 Injection)
Not yet recruiting
- Hematologic Malignancy
- BC3402 Injection
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Jinan University
Jan 10, 2023